TLL2: A Potential Drug Target and Biomarker (G7093)

Target Name: TLL2

NCBI ID: G7093

TLL2

TLL2: A Potential Drug Target and Biomarker

Tolloid-like 2 (TLL2) is a protein that is expressed in various tissues throughout the body. TLL2 has been shown to play a role in several cellular processes, including cell signaling, inflammation, and stress responses. Its functions make it an attractive target for drug development. In this article, we will discuss the potential drug target and biomarker properties of TLL2.

Potential Drug Target

TLL2 has been shown to interact with several protein molecules, including TGF-β1, NF-kappa-B, and NF-kappa-B-尾2. TGF-β1 and NF-kappa-B are known to play crucial roles in cell signaling and inflammation. The binding of TLL2 to these proteins suggests that TLL2 may be a potential drug target for diseases associated with these processes.

One of the potential benefits of targeting TLL2 is its potential to modulate inflammation and immune responses. Chronic inflammation is a major contributor to several diseases, including heart disease, cancer, and autoimmune disorders. TLL2 has been shown to regulate the production of pro-inflammatory cytokines, such as TNF-伪 and IL-1尾, which are associated with inflammation.

Another potential drug target for TLL2 is its role in cell signaling. TLL2 has been shown to play a role in several signaling pathways, including the TGF-β signaling pathway. This suggests that TLL2 may be a potential drug target for diseases associated with altered TGF-β signaling, such as cancer.

Biomarker

TLL2 has also been shown to serve as a potential biomarker for several diseases. The TLL2 gene has been shown to be significantly upregulated in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This suggests that TLL2 may be a potential biomarker for these diseases.

One of the potential benefits of TLL2 as a biomarker is its potential to identify disease-specific biomarkers. For example, TLL2 may be a potential biomarker for cancer, as its expression is known to be upregulated in several types of cancer. This suggests that TLL2 may be a useful indicator of disease severity and response to treatment.

Another potential benefit of TLL2 as a biomarker is its potential to identify potential therapeutic targets. The functions of TLL2 suggest that it may be a potential target for drugs that modulate its activity, such as inhibitors of TGF-β signaling pathway.

Conclusion

In conclusion, TLL2 is a protein that has been shown to play a role in several cellular processes, including cell signaling and inflammation. Its functions make it an attractive target for drug development. The potential drug target and biomarker properties of TLL2 make it an intriguing candidate for further research. Further studies are needed to fully understand its functions and potential as a drug target and biomarker.

Protein Name: Tolloid Like 2

Functions: Protease which specifically processes pro-lysyl oxidase. Required for the embryonic development. Predominant protease, which in the development, influences dorsal-ventral patterning and skeletogenesis

The "TLL2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TLL2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets